Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Feb 27, 2020, after the close
10-K filed Feb 27, 2020, 58 days after period end · 0001558370-20-001624
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $15.40M | $37.86M | $0.00 | — |
| Net Income | -$17.20M | $3.23M | -$25.87M | -$15.59M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.10 |
| $0.02 |
| -$0.18 |
| -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
